Lazertinib
Sign in to save this workspacePrimary targets: EGFR · FDA status: FDA Approved
Selectivity scorecard
KISS
97.47
Gini
0.674
CATDS
0.022
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Lazertinib. Strongest target: EGFR at 100.0% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | EGFR | 100.0% | 0.0% |
| 2 | ERBB2_HER2 | 99.7% | 0.3% |
| 3 | BLK | 99.0% | 1.0% |
| 4 | ERBB4_HER4 | 99.0% | 1.0% |
| 5 | JAK3 | 97.7% | 2.3% |
| 6 | FER | 97.7% | 2.3% |
| 7 | ROS_ROS1 | 97.0% | 3.0% |
| 8 | TXK | 97.0% | 3.0% |
| 9 | MLK1_MAP3K9 | 94.3% | 5.7% |
| 10 | MKK7 | 93.8% | 6.2% |
| 11 | ITK | 84.0% | 16.0% |
| 12 | AXL | 81.1% | 18.9% |
| 13 | MLK3_MAP3K11 | 79.5% | 20.5% |
| 14 | BTK | 77.1% | 22.9% |
| 15 | RIPK2 | 70.4% | 29.6% |
| 16 | TNK1 | 68.2% | 31.8% |
| 17 | SYK | 66.4% | 33.6% |
| 18 | EPHA6 | 63.3% | 36.7% |
| 19 | BMX_ETK | 58.9% | 41.1% |
| 20 | RET | 57.0% | 43.0% |
Selectivity landscape
Where Lazertinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Lazertinib.
Atlas insights for Lazertinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| EPT0291 | EPN | 0.844 |
| SRR23303752 | — | 0.843 |
| SRR10899984 | — | 0.835 |
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.831 |
| aMVAC.P_005_TURBT_S223 | — | 0.830 |
Annotations
Sign in to read and post annotations.
Loading…